TC Biopharm (Holdings) Plc (TCBP)
- Previous Close
5.92 - Open
6.10 - Bid 4.68 x 200
- Ask 7.55 x 200
- Day's Range
5.74 - 6.55 - 52 Week Range
2.11 - 1,140.00 - Volume
126,332 - Avg. Volume
210,630 - Market Cap (intraday)
3.602M - Beta (5Y Monthly) 0.11
- PE Ratio (TTM)
-- - EPS (TTM)
-203.22 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
tcbiopharm.comRecent News: TCBP
View More
Performance Overview: TCBP
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TCBP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TCBP
View MoreValuation Measures
Market Cap
3.39M
Enterprise Value
4.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.34
Enterprise Value/Revenue
1.83
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-108.91%
Return on Equity (ttm)
-1,217.48%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.59M
Diluted EPS (ttm)
-203.22
Balance Sheet and Cash Flow
Total Cash (mrq)
980.96k
Total Debt/Equity (mrq)
159.94%
Levered Free Cash Flow (ttm)
-6.85M
Research Analysis: TCBP
View MoreCompany Insights: TCBP
TCBP does not have Company Insights